Offer Letter, between BridgeBio Services, Inc. and Cameron Turtle, dated December 13, 2016, as amended on May 5, 2017

EX-10.25 8 d613995dex1025.htm EX-10.25 EX-10.25

Exhibit 10.25


December 13, 2016

Cameron Turtle



BridgeBio Pharma Employment

Dear Cameron:

BridgeBio Pharma LLC (the “Company”) would be lucky to have you on board as a member of our team. As an outstanding performer in both the science and business realms, you bring critical perspectives that would immediately increase the value of BridgeBio and positively impact our ability to help the patients we serve. In your role, you time would be split as follows:



Initially 50% Eidos, working to lead business development and corporate strategy for the familial amyloid cardiomyopathy program and working closely with Hoyoung (Board), me (Board, CEO) and Jonathan Fox (CMO, (he was the CMO at MyoKardia as well)). In this role, you will be expected to help us craft the corporate story, to develop and execute a BD / partnering strategy, to support the company IPO should we decide on that route in the next 18 months, to help build our presence in the clinical and investor community, and to think through internal recruiting, budgeting, and operations). You will also be a Board Observer at Eidos. Your title will be VP, Business Development and Operations at Eidos.



50% with BridgeBio. Helping diligence assets, execute deals, and ultimately to take the lead on 1-2 deals in terms of setting up the new company and playing a founding operating role as necessary. You will report directly to me in this role. Your title will be Sr. Director of Something (we should determine the ‘something’ together depending on what your ultimate career interests are -Sr. Director of Business Development or Corporate Development to start (title to be agreed with you)

Your effective date of hire (the “Start Date”) will be whenever you would like in Q1 of 2017 (preferably earlier in the quarter but dependent on your bonus payout from your current employer).

Your compensation for this position will be at the rate of $200,000 per year. There is no bonus program in the company as of yet, but as soon as there is, you will be a part of that with a performance target of 20%. Additionally, we would grant you an option to purchase 20,000 shares of the Company’s Interest. The exercise price of the Option will be at least equal to the fair market value of the Company’s common stock on the date of grant, and the Board of Directors may elect to seek a third party valuation of such fair market value, which could delay

the date that the Option is granted. The Option will be subject to the terms and conditions of the Company’s then-current stock option plan and form of stock option agreement. These options will vest as follows: 1/60th of the shares will vest on a monthly basis, such that 100% of such Common Units shall be vested on the 5 year anniversary. We will give you a one-time bonus as well to cover the cost of early exercise on this option. Finally, we would grant you an option to purchase 20,000 of Eidos Therapeutics Inc stock. The exercise price of the Option will be at least equal to the fair market value of on the date of grant. The Option will be subject to a four year vesting with a one year cliff.

It is understood that you are an “at-will” employee. You are not being offered employment for a definite period of time, and either you or the Company may terminate the employment relationship at any time and for any reason, with or without cause or prior notice and without additional compensation to you.

In making this offer, the Company understands that you are under no obligation to other current employers that might impair the performance by you of your duties as an employee of the Company.

The Immigration Reform and Control Act requires employers to verify the employment eligibility and identity of new employees. You will be required to complete a Form I-9 which will be provided to you before the Start Date. Please bring the appropriate documents listed on that form with you when you report for work. We will not be able to employ you if you fail to comply with this requirement. Also, this offer is subject to satisfactory reference checks if necessary.

This letter agreement constitutes the complete agreement between you and the Company, contain all of the terms of your employment with the Company and supersede any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company. This letter agreement may not be amended or modified, except by an express written agreement signed by both you and a duly authorized officer of the Company, although your job duties, title, reporting relationship, compensation and benefits may change from time to time.

Sincerely, Neil Kumar and the BridgeBio Team

/s/ Neil Kumar

I, Cameron Turtle, accept the offer terms proposed by Neil Kumar and the BridgeBio team.


/s/ Cameron Turtle

Cameron Turtle

May 1, 2017

Cameron W. Turtle



Transfer of Employment

Dear Cameron:

As you may know, BridgeBio Pharma LLC (the “Company”) is in the process of transferring all of its operating assets into separate corporate entities (the “Restructuring”). As part of the Restructuring, all Company employees are being transferred to BridgeBio Services, Inc. (“BridgeBio Services”), a newly formed subsidiary of the Company. Consequently, effective as of May 1, 2017 (the “Transfer Date”), your employment will be transferred to BridgeBio Services on an at-will basis, and you will no longer be employed by the Company. Except as otherwise described below, the terms and conditions of your employment will remain the same.

Payroll. Following the Transfer Date, you will be paid at the same rate and on the same schedule as before the Transfer Date, but BridgeBio Services will begin issuing your paychecks using its Employer Identification Number. Credit for all employment taxes paid by you and the Company prior to the Transfer Date will be transferred to BridgeBio Services without any additional action on your part.

Health and Welfare Benefits. Following the Transfer Date, you will be eligible to participate in an upgraded Platinum health and welfare benefit plan than which you are currently eligible to participate, subject to their terms and conditions. You have already completed new enrollment forms, and have been informed you will not be credited for amounts you have paid toward any deductibles and out-of-pocket maximums during the plan year prior to the Transfer Date (such amounts, the “Deductibles”). In order to compensate for the loss of such credit, BridgeBio Services will make a cash payment to you in an amount equal to the Deductibles plus 35% which is an estimate equal to the aggregate withholding and employment taxes due by you in connection with the Deductibles and the additional amount, such payment to be made by the end of May provided you include an EOB to support the deductible amount met to date.

Management Incentive Units. Any Management Incentive Units (“MIUs”) previously granted to you will remain outstanding and eligible to vest in accordance with their terms, provided that, upon your signature below, the agreement(s) evidencing your MIUs will be deemed amended to provide that your MIUs will vest based upon your continued employment with BridgeBio Services. The terms and conditions of your MIUs will otherwise remain the same.

Accrued PTO. In connection with your transfer of employment, your accrued and unused vacation days and paid time off (collectively, “Accrued PTO”) will be transferred to BridgeBio Services, and you will be entitled to use your Accrued PTO in accordance with the same policies in effect prior to the Transfer Date. By signing this letter, you consent to the foregoing transfer of Accrued PTO to the extent necessary.

Please indicate your agreement to the foregoing by signing in the space provided below and returning it to Lena Pang or Kristie Dang by May 5, 2017. Should you have any questions regarding your transfer of employment, please contact Asha Rajagopal at ***@***.


/s/ Neil Kumar

Name:   Neil Kumar
Title:   CEO



May 5, 2017


/s/ Cameron Turtle

Cameron W. Turtle